Changes in Hong Kong stocks | Xinwei Medical-B (06609) rose by more than 11%, executives increased their shareholding in the company. Currently, the company has launched an A-share IPO plan

The Zhitong Finance App learned that Xinwei Medical-B (06609) rose by more than 11%. As of press release, it had risen 11.17% to HK$60.7, with a turnover of HK$7.681 million.

According to the news, on December 12, 2025, Xinwei Medical-B announced that it plans to sell 1 million domestic shares to Zhang Han at a 1.10% discount, with a net raise of HK$43.25 million. CITIC Construction Investment pointed out that it is expected that after the transaction is completed, it will further increase the company's working cash reserves. It is expected that all of this cash will be used for investment/mergers and acquisitions in the medical device industry by the end of 2028, which is expected to expand the company's product portfolio and help the company grow sustainably in the long term.

The bank believes that the company's executives have increased their shareholding with their own capital, which shows management's confidence in the progress of the company's A-share IPO and the development of medium- to long-term strategies. Previously, the company published an article on its official account on September 15, 2025. The company's A-share IPO launch meeting was successfully held, which means that the company is expected to further enhance capital market liquidity through the A-share IPO listing in the future. In addition, the company is actively promoting the medical device registration process for interventional brain-computer interface products, and is expected to complete the first human clinical enrollment by the end of 2026.